Alerts will be sent to your verified email
Verify EmailNOVARTIND
Novartis
|
Panacea Biotec
|
Beta Drugs
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
-5.28 % | n/a | n/a |
Financials
|
|||
5 yr Average ROE
|
8.0 % | 36.5 % | 21.73 % |
5yr average Equity Multiplier
|
2.72 | 0.36 | 1.75 |
5yr Average Asset Turnover Ratio
|
0.18 | 0.41 | 1.04 |
5yr Avg Net Profit Margin
|
17.12 % | 26.1 % | 11.97 % |
Price to Book
|
2.78 | 2.95 | 0.0 |
P/E
|
21.21 | 214.56 | 43.21 |
5yr Avg Cash Conversion Cycle
|
-23.33 Days | -170.26 Days | 15.7 Days |
Inventory Days
|
44.27 Days | 120.03 Days | 43.83 Days |
Days Receivable
|
38.18 Days | 42.2 Days | 87.61 Days |
Days Payable
|
124.28 Days | 325.14 Days | 113.94 Days |
5yr Average Interest Coverage Ratio
|
65.43 | 2.7 | 13.71 |
5yr Avg ROCE
|
5.91 % | -2.79 % | 27.85 % |
5yr Avg Operating Profit Margin
|
15.15 % | -3.85 % | 21.58 % |
5 yr average Debt to Equity
|
0.0 | -0.69 | 0.23 |
5yr CAGR Net Profit
|
37.01 % | -43.68 % | 31.07 % |
5yr Average Return on Assets
|
3.13 % | 9.32 % | 12.53 % |
Shareholdings
|
|||
Promoter Holding
|
70.68 % | 72.48 % | 66.73 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.0 | -1.11 % | 0.02 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
Novartis
|
Panacea Biotec
|
Beta Drugs
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|